Clinical Trials Logo

Filter by:
NCT ID: NCT00784069 Completed - Hygiene Clinical Trials

Dermacyd Breeze (Lactic Acid) Pocket BR - Photo Evaluation

Start date: October 2008
Phase: Phase 3
Study type: Interventional

To demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd Breeze (Lactic Acid) Pocket BR.

NCT ID: NCT00784056 Completed - Hygiene Clinical Trials

Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Photo Evaluation

Start date: August 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd PHDETINLYN Tangerine Mix (Lactic Acid).

NCT ID: NCT00783939 Completed - Hygiene Clinical Trials

Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Safety.

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to prove the safety in normal conditions of useof the product Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid).

NCT ID: NCT00783861 Completed - Hygiene Clinical Trials

Dermacyd Femina (Lactic Acid) Pocket BR - Compatibility

Start date: October 2008
Phase: Phase 3
Study type: Interventional

To demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd Femina (Lactic Acid) Pocket BR.

NCT ID: NCT00783835 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a clinical condition beginning in childhood and is characterized by inadequate levels of attention, hyperactivity and impulsiveness.

NCT ID: NCT00783666 Completed - Hygiene Clinical Trials

Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation

Start date: August 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd PHDETINBACK Tangerine Mix (Lactic Acid).

NCT ID: NCT00783640 Completed - Hygiene Clinical Trials

Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation

Start date: October 2008
Phase: Phase 3
Study type: Interventional

To demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd Femina (Lactic Acid) Pocket BR.

NCT ID: NCT00781391 Completed - Stroke Clinical Trials

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

EngageAFTIMI48
Start date: November 2008
Phase: Phase 3
Study type: Interventional

This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation. Patients will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, & Warfarin. The expected duration of the study is 24 months.

NCT ID: NCT00781300 Completed - Ocular Hypertension Clinical Trials

Intraocular Pressure With Loteprednol and Dexamethasone

Start date: March 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare intraocular pressure (IOP) changes after pterygium surgery among patients using loteprednol and dexamethasone during the postoperative period.

NCT ID: NCT00780780 Completed - Clinical trials for Diabetic Macular Edema

Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema

NEVANAC
Start date: July 2007
Phase: Phase 3
Study type: Interventional

Diabetics retinopathy remains the major threat to sight in the working age population in the developed world. Furthermore, it is increasing as a major cause of blindness in other parts of the world, especially developing countries. Diabetic macular edema (DME) is a manifestation of diabetic retinopathy that produces loss of central vision. The triamcinolone intravitreal injection (1-4mg) is indicated to treatment of diabetic macular edema and it is considered an important treatment since it improves the visual acuity of patients with resolution of edema. Nepafenac is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop (0.1% solution). Nepafenac is manufactured by Alcon as Nevanac. It is approved by FDA as well as ANVISA. Pre-clinical studies suggest this medication showed efficacy to treat ocular posterior segment inflammation. The purpose of this study is evaluate the efficacy of intravitreal triamcinolone associated with nepafenac eye drops as treatment of diabetic macular edema.